Vizsgálati helyszín

University Gastroenterology

Providence, Rhode Island 02905, Egyesült ÁllamokMég nincs intézményhez kötve

17futó vizsgálat
3lezárt vizsgálat

Az itteni vizsgálatok

Miről szól a helyszín 20 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek: Colitis ulcerosa8 vizsgálat
Crohn-betegség8 vizsgálat
Zsírmáj (MASLD/MASH)3 vizsgálat
Elhízás2 vizsgálat
Irritable bowel syndrome2 vizsgálat
Liver cirrhosis1 vizsgálat
Fázis: 3. fázis10 vizsgálat
2. fázis6 vizsgálat
4. fázis3 vizsgálat
2/3. fázis1 vizsgálat
Állapot: Toboroz10 vizsgálat
Fut, nem toboroz7 vizsgálat
Lezárult3 vizsgálat
Fő szponzor: Eli Lilly and Company7 vizsgálat
Hoffmann-La Roche4 vizsgálat
Takeda4 vizsgálat
Janssen Research & Development, LLC2 vizsgálat
Agomab Spain S.L.U.1 vizsgálat
és még 2

Futó vizsgálatok

Toboroz
NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease
NCT07683325· 2. fázis· Agomab Spain S.L.U.· Forrás
Contact: Agomab Clinical Operations
Toboroz
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT07545759· 2. fázis· Eli Lilly and Company· Forrás
Contact: Lisa Mueller (principal investigator)
Toboroz
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
NCT07545772· 2. fázis· Eli Lilly and Company· Forrás
Contact: Lisa Mueller (principal investigator)
Toboroz
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· 3. fázis· Eli Lilly and Company· Forrás
Contact: Eric Newton (principal investigator)
Toboroz
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099· 3. fázis· Eli Lilly and Company· Forrás
Contact: Lisa Mueller (principal investigator)
Toboroz
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086· 3. fázis· Eli Lilly and Company· Forrás
Contact: Lisa Mueller (principal investigator)
Toboroz
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
NCT06581328· 4. fázis· Takeda· Forrás
Contact: Lisa Mueller (principal investigator)
Toboroz
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
NCT06095128· 4. fázis· Takeda· Forrás
Fut, nem toboroz
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
NCT06045754· 4. fázis· Takeda· Forrás
Fut, nem toboroz
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950· 2. fázis· Takeda· Forrás
Fut, nem toboroz
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
NCT04232553· 3. fázis· Eli Lilly and Company· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Lezárt vizsgálatok

Lezárult
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05767021· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
NCT04971785· 2. fázis· Gilead Sciences· Forrás
Lezárult
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
NCT04321031· 2. fázis· Pfizer· Forrás

Helyszínadatok: ClinicalTrials.govFrissítve: 2026. nov. 13.

Hibát jelzek